Adam J Gilbert

US Patent:

20230009153, Jan 12, 2023

Filed:

Aug 4, 2021

Appl. No.:

17/393463

Inventors:

- New York NY, US
Matthew Frank Brown - Stonington CT, US
Ye Che - Groton CT, US
Jotham Wadsworth Coe - Niantic CT, US
Mark Edward Flanagan - Gales Ferry CT, US
Adam Matthew Gilbert - Guilford CT, US
Matthew Merrill Hayward - Old Lyme CT, US
Jonathan David Langille - Quaker Hill CT, US
Justin Ian Montgomery - Ledyard CT, US
Jean-Baptiste Telliez - Lexington MA, US
Rayomand Jal Unwalla - Bedford MA, US
John I. Trujillo - Ledyard CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 471/04
A61K 31/4523
C07D 471/08
C07D 487/04
C07D 487/10
C07D 498/04

Abstract:

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

US Patent:

20210309659, Oct 7, 2021

Filed:

Jun 1, 2021

Appl. No.:

17/335666

Inventors:

- New York NY, US
Christopher Ryan Butler - Canton MA, US
Elizabeth Mary Beck - Oxford, GB
Michael Aaron Brodney - Newton MA, US
Matthew Frank Brown - Stonington CT, US
Laura Ann McAllister - Arlington MA, US
Erik Alphie LaChapelle - Uncasville CT, US
Adam Matthew Gilbert - Guilford CT, US

International Classification:

C07D 471/04
A61P 25/00
A61P 25/16
A61P 25/18
A61P 25/28
A61K 31/437

Abstract:

The present invention provides, in part, compounds of Formula I:or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R, R, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

US Patent:

20200262833, Aug 20, 2020

Filed:

Jun 14, 2018

Appl. No.:

16/625202

Inventors:

- New York NY, US
Michael Aaron Brodney - Newton MA, US
Matthew Frank Brown - Stonington CT, US
Christopher Ryan Butler - Canton MA, US
Adam Matthew Gilbert - Guilford CT, US
Erik Alphie Lachapelle - Uncasville CT, US
Laura Ann McAllister - Arlington MA, US
Daniel Paul Uccello - Colchester CT, US
Lei Zhang - Auburndale MA, US

International Classification:

C07D 471/04
A61P 25/28
A61P 25/30
A61P 25/18

Abstract:

The present invention provides, in part, compounds of Formula I, or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: (R)a, (R)b, (R)c, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

US Patent:

20200207762, Jul 2, 2020

Filed:

Feb 21, 2020

Appl. No.:

16/797966

Inventors:

- New York NY, US
Christopher Ryan Butler - Canton MA, US
Elizabeth Mary Beck - Oxford, GB
Michael Aaron Brodney - Newton MA, US
Matthew Frank Brown - Stonington CT, US
Laura Ann McAllister - Arlington MA, US
Erik Alphie LaChapelle - Uncasville CT, US
Adam Matthew Gilbert - Guilford CT, US

International Classification:

C07D 471/04
A61P 25/28
A61P 25/18
A61P 25/16
A61P 25/00

Abstract:

The present invention provides, in part, compounds of Formula I:or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R, R, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

US Patent:

20190002466, Jan 3, 2019

Filed:

Apr 19, 2016

Appl. No.:

15/569874

Inventors:

- New York NY, US
Matthew Frank BROWN - Stonington CT, US
Ye CHE - Groton CT, US
Mark Edward FLANAGAN - Gales Ferry CT, US
Adam Matthew GILBERT - Guilford CT, US
Matthew Merrill HAYWARD - Old Lyme CT, US
Jean-Baptiste TELLIEZ - Lexington MA, US
Rayomand Jal UNWALLA - Bedford MA, US
John I. TRUJILLO - Ledyard CT, US
Sidney Xi LIANG - Bethany CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 487/04

Abstract:

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides, and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

US Patent:

20180002331, Jan 4, 2018

Filed:

Jun 29, 2017

Appl. No.:

15/637071

Inventors:

- New York NY, US
Christopher Ryan Butler - Canton MA, US
Elizabeth Mary Beck - Oxford, GB
Michael Aaron Brodney - Newton MA, US
Matthew Frank Brown - Stonington CT, US
Laura Ann McAllister - Arlington MA, US
Erik Alphie LaChapelle - Uncasville CT, US
Adam Matthew Gilbert - Guilford CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 471/04

Abstract:

The present invention provides, in part, compounds of Formula I:or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R, R, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

US Patent:

20170247372, Aug 31, 2017

Filed:

Mar 1, 2017

Appl. No.:

15/446500

Inventors:

- New York NY, US
Matthew Frank Brown - Stonington CT, US
Ye Che - Groton CT, US
Jotham Wadsworth Coe - Niantic CT, US
Mark Edward Flanagan - Gales Ferry CT, US
Adam Matthew Gilbert - Guilford CT, US
Matthew Merrill Hayward - Old Lyme CT, US
Jonathan David Langille - Quaker Hill CT, US
Justin Ian Montgomery - Ledyard CT, US
Jean-Baptiste Telliez - Lexington MA, US
Rayomand Jal Unwalla - Bedford MA, US
John I. Trujillo - Ledyard CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 471/04
C07D 487/04
C07D 487/10
C07D 471/08
C07D 498/04

Abstract:

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

US Patent:

20150158864, Jun 11, 2015

Filed:

Dec 3, 2014

Appl. No.:

14/559294

Inventors:

- New York NY, US
Matthew Frank Brown - Stonington CT, US
Ye Che - Groton CT, US
Jotham Wadsworth Coe - Niantic CT, US
Mark Edward Flanagan - Gales Ferry CT, US
Adam Matthew Gilbert - Guilford CT, US
Matthew Merrill Hayward - Old Lyme CT, US
Jonathan David Langille - Quaker Hill CT, US
Justin Ian Montgomery - Ledyard CT, US
Jean-Baptiste Telliez - Lexington MA, US
Rayomand Jal Unwalla - Bedford MA, US

International Classification:

C07D 471/04
C07D 487/10
C07D 498/04
C07D 487/04
C07D 471/08

Abstract:

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.